Boston Scientific launches MRI-safe Resonate devices with HeartLogic diagnostic in U.S.

Boston Scientific (NYSE:BSX) launched today its Resonate implantable cardioverter defibrillator and cardiac resynchronization therapy defibrillator systems with the HeartLogic heart failure diagnostic tool. The devices are approved by the FDA for conditional use in an MRI environment, the company reported. Boston Scientific’s HeartLogic diagnostic warns doctors of worsening heart failure, collecting data from sensors monitoring heart sounds, thoracic impedance, heart rate and activity and respiration rate and volume. The company touted its alert system as the first and only of its kind in an implantable device with an observed sensitivity of 70% and the ability to provide weeks of advance notice. “The HeartLogic Diagnostic provides physicians the ability to pivot from reactive heart failure treatment to proactive care with a goal of improving patient outcomes and reducing heart failure-related hospitalizations,” Dr. Kenneth Stein, SVP & CMO of Boston Scientific’s rhythm management and global health policy unit, said in prepared remarks. “We believe the new features included in this family of devices offer physicians an unprecedented level of confidence when caring for patients with heart failure.” The CRT-Ds in the Resonate portfolio also feature SmartCRT technology, the company reported, which allows doctors to customize where, when and how to pace the lower chambers of the heart. Boston Scientific has started recruiting patients for...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiovascular Diagnostics Food & Drug Administration (FDA) Regulatory/Compliance Wall Street Beat Boston Scientific Source Type: news